• August 13, 2019

In May, U.S.-based Abbott Labs secured the top spot in India’s growing pharmaceutical industry with its US$ billion takeover of Piramal. In , Ajay Piramal promoted Piramal Healthcare sold off its main formulation business to Abbott India for over INR 17, crore and announced a buy-back of . When US-based global health care major Abbott acquired the formulations business of Piramal Healthcare in a $billion deal in , it had.

Author: Yozshuzuru Yozshum
Country: Jordan
Language: English (Spanish)
Genre: Photos
Published (Last): 28 November 2009
Pages: 478
PDF File Size: 16.9 Mb
ePub File Size: 10.11 Mb
ISBN: 917-4-88278-517-6
Downloads: 62042
Price: Free* [*Free Regsitration Required]
Uploader: Kigara

Nationalisation of Banks Cadbury’s worms of graft: This is the 2nd-largest deal ever in the Indian pharma industry, just behind Daiichi Sankyo’s takeover of Ranbaxy in All Comments Your Activity. It will continue its drug discovery and research through Piramal Life Sciences Ltd.

Abbott buys Piramal’s pharma arm for $bn – Times of India

Piramal’s Healthcare Solutions business employs over 5, people in India. Today, in healthcare, PEL is one of the leading players globally in CRAMS custom research and manufacturing services as well as in the critical care segment of inhalation and injectable anaesthetics.

Del From Book to Bank: Danzon adds that the emerging business plan for generics companies is essentially around selling to pharmacists, not physicians.

The hunter has become the hunted. Login from existing account Facebook Google Email. Chaudhuri acknowledges those new realities, but with a patriotic tinge.

It also has a strong presence in the OTC segment in India. The Abbott-Piramal deal is the latest in a wave of consolidation within the global pharmaceutical industry over the deak few years.


According to Wharton faculty and industry experts, changing global business models and the deak needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions. More than one voice suggested the company return a part of the cash to its shareholders.

Unilever’s Bargain Offer Economic Milestone: Creating a faster, nimbler HUL. Keep me signed in. The earlier regime dral patents on pharmaceutical processes but not on pharmaceutical products, allowing companies to reverse-engineer copies of the branded and patented drugs of western companies.

Fortis again pushes back date to complete RHT Health deal; auditor resigns. Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and pay down debt.

Log in Keep me signed in. It entered into financial services focused on real estate. A key differentiator here is that unlike in the U. The Thomson Reuters Trust Principles.

Seven years after Piramal deal, Abbott way off revenue target | Business Standard News

Read Post a comment. He also acknowledged that the company had become a conglomerate and the structure made Piramal Enterprises difficult to understand. Help us delete comments that do plramal follow these guidelines by marking them offensive.

Abbott has been operating in India for of its years, and has popular pharmaceutical brands including the antacid Digene and painkiller Brufen. The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry abboott invest in the remaining business.


Abbott will pay Rs per share. It allows Abbott to commercialize two dozen Zydus Cadila drugs in 15 emerging markets. The deal, subject to Piramal Healthcare shareholder approval, is expected to close in the second half of By clicking Login, you agree to the Mnacritique privacy policy.

We have sent you a verification email. Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western pjramal emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business India.

Seven years after Piramal deal, Abbott way off revenue target

The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Its Structured Investments Division invests in various sectors including infrastructure. Ajay Piramal has also taken over as chairman of Shriram Capital.

The Abbott-Piramal combine reports to him, but he notes it will be run as a standalone business unit after the merger takes effect later this year.

Fortunately for me, there are plenty of those in Asia at the moment.